Industry-Leading Training on Lateral Flow Assay Development Returns with New Opportunities
CARLSBAD, Calif., Dec. 12, 2024 /PRNewswire/ — DCN Dx, specializing in lateral flow diagnostics development and manufacturing and IVD regulatory consulting and clinical research, has announced the 2025 dates for its Basic Lateral Flow Training (BLFT) Course. This hands-on training program will take place at DCN Dx’s state-of-the-art facility in Carlsbad, California, on the following dates:
Participants will gain unparalleled insight into the end-to-end lateral flow assay development process, including design control, material selection, manufacturing considerations, and troubleshooting strategies.
“This course is designed to equip participants with the skills and knowledge needed to tackle real-world challenges in lateral flow assay development,” said Mitzi Rettinger, Chief Revenue Officer at DCN Dx. “The insights shared in the BLFT Course have empowered hundreds of professionals to improve the quality and efficiency of their LFAs.”
Attendees will benefit from a comprehensive curriculum delivered through interactive lectures, lab demonstrations, and hands-on activities. The course covers key topics such as reader technologies, stability studies, and cassette design—all essential for creating reliable diagnostic tools.
“Lateral flow assays play a critical role in global diagnostics,” said Charlie Mamrak, CEO of DCN Dx. Ensuring that professionals have access to high-quality training helps to drive innovation, improve diagnostic accessibility—especially at the point-of-care—and ultimately support better health outcomes worldwide.”
Special Offer:
Register for any 2025 course by January 5 to take advantage of a discounted rate of $2,995—$1,905 off the regular price of $4,900. Use promo code BLFT2025 at checkout.
To learn more about the Basic Lateral Flow Training Course or to register, visit dcndx.com.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory services.
DCN Dx’s personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. They can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, DCN Dx’s clinical research expertise extends to any in vitro diagnostic, all with a focus on innovation, usability, and performance.
With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
For more information contact:
Mitzi Rettinger
Chief Revenue Officer, DCN Dx
Main: (760) 804-3886
Mobile: (512) 431-5836
387568@email4pr.com
SOURCE DCN Dx
'Beyond Structure, Predicting Function' SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co.,…
SHERIDAN, Wyo., Dec 25, 2024 /PRNewswire/ -- Casect, LLC, a medical education technology company, announces…
FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced…
- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be…
If you are male and in your 40's and 50's and feel your testosterone levels…
Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…